细胞特异性核酸适配体筛选新策略的研究进展

核酸适配体(aptamer)是在体外采用指数富集的配基系统进化技术(systematic evolution of ligands by exponential enrichment, SELEX)从人工合成的随机寡核苷酸文库中筛选得到的一段寡核苷酸序列(RNA或DNA),能折叠成特定的三维空间结构同靶物质进行高特异性与高亲和性的结合。近年来,以全细胞为靶标筛选(cell-SELEX)获得的核酸适配体在疾病相关的领域有很大的应用潜力,尤其在细胞分子的识别、生物标志物的发现等方面,但cell-SELEX的过程复杂、难度大及获得的核酸适配体性能不佳等问题仍然制约着细胞特异性核酸适配体的进一步发展,如何高效地筛选获得核酸适配体是其应用的关键。本文总结了目前在cell-SELEX技术基础上发展起来的新方法、新策略及核酸适配体在肿瘤研究中的应用,望为相关科研人员的研究提供参考。     

SELEX技术及近年研究进展

指数富集配体系统进化技术(Systematic evolution of ligand by exponential enrichment,SELEX)是近20年来出现的一种新型体外筛选技术。该技术将文库技术与筛选技术相结合,从核酸文库中筛选出的一段核酸分子:配基-适配子(aptamer);适配子与抗体类似,可以与相应靶物质特异性结合。SELEX技术筛选适配子的技术有快速的进步,而适配子也被应用到医学生物学等各个方面。在HIV等病毒学研究与治疗方面,SELEX的应用也有了可观的进展,多种病毒的相关适配子被筛选出来,为病毒相关疾病的防治提供了新的方向。本文主要就近三年来的SELEX技术发展状况及在应用上的发展进行简要综述。     

化学修饰寡核苷酸在核酸配基扩增技术中的应用

核酸酸基扩增技术（SELEX)可从极大容量的随机寡核苷酸文库中筛选得到与靶分子高特异性和高亲和力结合的核酸配基。对寡核苷酸进行化学修饰,可以提高核酸配基的稳定性,增加其功能多样性及生物利用度。SELEX在基础研究、诊断和治疗试剂的研制及药物筛选等领域有广泛用途。     

人FcγRI特异性核酸适配体的体外筛选及鉴定北大核心CSCD

人中性粒细胞FcγRI(即CD64),Ig G Fc高亲和力受体之一,是早期诊断脓毒血症和系统性细菌感染的一个灵敏和特异的新标志物;目前,采用流式细胞计量术测定,难以在一般实验室开展。本研究旨在应用新型的体外筛选技术——指数富集配基的系统进化(systematic evolution of ligands by exponential enrichment,SELEX)技术——从体外合成的随机寡核苷酸文库中筛选人FcγRI的高亲和力和高特异性的核酸适配体(aptamer)。本文以人FcγRI为靶标,将其固定在羧基活化磁珠上,进行SELEX筛选。经过8轮筛选,共获得3个重点研究的单克隆适配体。生物信息学分析结果显示,人FcγRI适配体的模拟二级结构以茎-环和G-四聚体为主,可能是FcγRI与适配体的作用位点,G-T错配常见。流式细胞计量术和荧光显微镜分析显示,筛选出的典型单克隆适配体解离常数(the dissociation constant,Kd)均达到纳摩尔水平,而且适配体只与脓毒血症中性粒细胞结合,具有良好的亲和力和特异性。本研究表明,通过SELEX技术,成功获取了人FcγRI特异性核酸适配体,为以此适配体为分子探针,进一步建立用于脓毒血症早期诊断的新方法奠定了基础。     

人FcγRI特异性核酸适配体的体外筛选及鉴定

人中性粒细胞FcγRI(即CD64),Ig G Fc高亲和力受体之一,是早期诊断脓毒血症和系统性细菌感染的一个灵敏和特异的新标志物;目前,采用流式细胞计量术测定,难以在一般实验室开展。本研究旨在应用新型的体外筛选技术——指数富集配基的系统进化(systematic evolution of ligands by exponential enrichment,SELEX)技术——从体外合成的随机寡核苷酸文库中筛选人FcγRI的高亲和力和高特异性的核酸适配体(aptamer)。本文以人FcγRI为靶标,将其固定在羧基活化磁珠上,进行SELEX筛选。经过8轮筛选,共获得3个重点研究的单克隆适配体。生物信息学分析结果显示,人FcγRI适配体的模拟二级结构以茎-环和G-四聚体为主,可能是FcγRI与适配体的作用位点,G-T错配常见。流式细胞计量术和荧光显微镜分析显示,筛选出的典型单克隆适配体解离常数(the dissociation constant,Kd)均达到纳摩尔水平,而且适配体只与脓毒血症中性粒细胞结合,具有良好的亲和力和特异性。本研究表明,通过SELEX技术,成功获取了人FcγRI特异性核酸适配体,为以此适配体为分子探针,进一步建立用于脓毒血症早期诊断的新方法奠定了基础。     

核酸适配体结合纳米材料用于肿瘤靶向治疗

核酸适配体(aptamer)是一类由指数富集配体系统进化(systematic evolution of ligands by exponential enrichment,SELEX)技术筛选出的RNA和单链DNA寡核苷酸片段。因其非同寻常的分子识别能力及结构特性,核酸适配体已经成为最具有应用前景的生物分子之一,综述了核酸适配体结合不同的纳米材料在肿瘤靶向治疗上的应用。     

RNA适体研究及其在医药上的应用

核酸适体（nucleic acid aptamer）是从人工合成的随机单链核酸库中筛选出的特异性与靶物质高度亲和的核酸分子,包括DNA适体和RNA适体. 体外获得核酸适体的方法称为指数富集配体系统进化技术,即SELEX（systematic evolution of ligands by exponential enrichment）. 在SELEX技术获得的核酸适体中,RNA适体因其结构的多样性而具有靶分子广、亲和力高、特异性强等特点. 同时,相比传统抗体,RNA适体分子量小、易改造修饰、制备方便且无免疫原性. 因此,RNA适体在基础研究、临床诊断、药物研制等方面展现了广阔的应用前景. 本文综述了RNA适体的产生、特点、作用方式、优势与局限性,并详细介绍了其在医药研究领域的应用.     

核酸适配体筛选的改良与优化策略

核酸适配体以其类似抗体的功能及诸多优于抗体的特点引起人们的广泛关注,如何利用指数富集的配基系统进化技术(SELEX技术)来高效地筛选核酸适配体是其应用的关键。结合近些年核酸适配体的研究进展,为提高筛选效率及核酸适配体性能,针对适配体筛选三大不同环节所做的尝试及改良进行相关的阐述,包括初始随机寡核苷酸文库的设计与修饰、筛选过程所用方法及次级文库的制备、筛选过程后(Post-SELEX)核酸适配体性能的优化等;特别比较了筛选方法包括毛细管电泳SELEX、细胞SELEX、磁珠SELEX、加尾SELEX、微流控SELEX、微阵列SELEX和高通量SELEX,以及次级文库的制备方法诸如不对称PCR法、λ核酸外切酶法、磁珠法、不等长PCR法、综合性方法等;对核酸适配体发展面临的问题及发展前景进行探讨,以期为相关科研人员的研究提供参考。     

指数富集配基的系统进化原理及应用进展

过去十几年,指数富集配基的系统进化（SELEX）技术得到了充分的发展,目前已经成为在数量众多的靶分子中,高亲和性和特异性地确定适配子的一种崭新的方法.SELEX的流程即是人工合成随机寡核苷酸序列、适配子筛选、扩增、再循环的过程.在这一过程中,适配子修饰基团文库的应用使得SELEX流程更加经济、快捷、高通量.回顾了SELEX的研究和应用,期待着这一方法能够在理论和实践上得到进一步的发展.     

核酸适配体的体外筛选方法的最新研究进展

核酸适配体是用配体指数富集系统进化技术(SELEX)在体外筛选得到的一小段寡核苷酸序列,能够选择性的与不同的靶标特异性的结合,包括蛋白质、小分子、有机物、金属离子、药物等,具有高亲和力和高特异性。这项技术的诸多优势,使其迅速得到重视,核酸适配体在生物传感器、基因芯片、新药开发、纳米技术等诸多方面应用广泛。但是传统的SELEX方法操作繁琐,筛选周期长,需要几个月的时间才能筛选出与靶标具有高特异性的核酸适配体。随着SELEX的快速发展,近年来出现了很多新型的筛选方法,这些新的方法大大提高了筛选周期,极大的提高了筛选效率,拓展了核酸适配体的应用。总结介绍了近三年来出现的几种新型的核酸适配体的筛选方法,包括氧化石墨烯SELEX(Multiple GO-SELEX)、单壁碳纳米管辅助细胞SELEX(SWCNTs-assisted cell-SELEX)、基于芯片的细胞SELEX(on-chip Cell-SELEX)、序列构造SELEX(Sequence-constructive SELEX)、高保真SELEX(High-Fidelity SELEX),有助于人们进一步了解、认识核酸适配体筛选技术的发展现状,更好促进核酸适体在各个领域中的应用前景。     

以完整细胞为靶子的SELEX技术研究进展

指数富集的配体系统进化（SELEX）是一种从大容量寡核苷酸文库中经反复分离扩增步骤得到针对靶分子的高亲和力、高特异性核酸配基——适配体的体外筛选技术。自1990年以来,SELEX技术得到了迅猛发展,筛选的靶分子已由最初的单一物质发展到完整的动物细胞、细菌病原体等复杂靶子。以完整细胞为靶子的SELEX技术有其独特的技术优势,可以在筛选细胞上特定靶分子未知的情况下进行筛选,为药物筛选、临床诊断、疾病治疗和基础医学研究等带来了新的思路和方法。随着对适配体研究的深入,尤其是纳米材料与其相结合应用,该技术将在肿瘤诊断治疗及微生物检测领域具有更为广泛的应用前景。     

SELEX技术在神经系统疾病研究中的应用

配体指数级富集系统进化（systematic evolution of ligands by exponential enrichment,SELEX）技术是一种组合化学技术,可经过反复筛选扩增得到针对靶分子的高亲和力和高特异性的适配子.适配子通过识别、结合特定靶分子并对其进行功能调控从而达到对疾病诊断和治疗的目的 .近年来SELEX技术在神经系统功能和疾病研究中的应用越来越多.现已经筛选出针对朊蛋白、肌腱蛋白-C、β-淀粉样肽、乙酰胆碱受体的自身抗体等靶标的适配子,促进了对朊病毒病、脑肿瘤、阿茨海默病、重症肌无力等神经系统疾病的诊断和治疗研究,为这些疾病的诊治提供了新的研究工具.     

Parasite-specific aptamers as biosynthetic reagents and potential pharmaceuticals

Aptamers are short, synthetic nucleic acid molecules. They are generated by a Darwinian-type in vitro evolution method known as 'systematic evolution of ligands by exponential enrichment' (SELEX). SELEX represents an experimental platform to identify rare ligands with predetermined functionality from combinatorial nucleic acid libraries. Since its discovery about 20 years ago the method has been instrumental in identifying a large number of aptamers that recognize targets of very different chemistry and molecular complexity. Although aptamers have been converted into sophisticated biomolecular tools for a diverse set of technologies, only a limited number of aptamers have been selected as binding reagents for parasites or parasite-derived molecules. Here the published examples of aptamers that target Leishmania-, Trypanosoma- and Plasmodia-specific molecules are reviewed.     

SELEX--a (r)evolutionary method to generate high-affinity nucleic acid ligands

SELEX stands for systematic evolution of ligands by exponential enrichment. This method, described primarily in 1990 [Ellington, A.D., Szostak, J.W., 1990. In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818-822; Tuerk, C., Gold, L., 1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505-510] aims at the development of aptamers, which are oligonucleotides (RNA or ssDNA) binding to their target with high selectivity and sensitivity because of their three-dimensional shape. Aptamers are all new ligands with a high affinity for considerably differing molecules ranging from large targets as proteins over peptides, complex molecules to drugs and organic small molecules or even metal ions. Aptamers are widely used, including medical and pharmaceutical basic research, drug development, diagnosis, and therapy. Analytical and separation tools bearing aptamers as molecular recognition and binding elements are another big field of application. Moreover, aptamers are used for the investigation of binding phenomena in proteomics. The SELEX method was modified over the years in different ways to become more efficient and less time consuming, to reach higher affinities of the aptamers selected and for automation of the process. This review is focused on the development of aptamers by use of SELEX and gives an overview about technologies, advantages, limitations, and applications of aptamers.     

SELEX技术在病毒感染诊断和治疗中的应用

指数富集的配体系统进化（SELEX）技术是一种新的组合化学技术,它利用人工合成的随机寡核苷酸文库,通过体外多轮筛选与扩增,获得能与靶物质特异性结合的寡核苷酸适体。适体的靶分子广泛,包括病毒代谢相关产物,且与靶物质结合的亲和力高、特异性强,在体内代谢及稳定性等方面优于抗体。在细胞和动物模型中,适体显示出很多优于抗体的特性,而且已经有适体作为药物进入临床试验阶段。这种体外筛选技术是一种较成熟的技术,由此产生的适体具有较好的理化特征,可以抑制病毒复制感染的各个阶段,而且在病毒感染所引发的相关疾病诊断和治疗等方面具有较好的应用前景。     

Selection of RNA aptamers against recombinant transforming growth factor-beta type III receptor displayed on cell surface

In most cases, anti-protein aptamers are selected by systematic evolution of ligands by exponential enrichment (SELEX) using purified recombinant protein targets. Cell surface proteins, however, are not easy targets for SELEX due to the difficulties associated with their purification. Here, we developed a novel SELEX procedure (referred to as TECS-SELEX) in which cell-surface displayed recombinant protein is directly used as the selection target. Using this method, we isolated RNA aptamers against transforming growth factor-beta type III receptor expressed on Chinese hamster ovary (CHO) cells. One of the RNA aptamers has a dissociation constant in the 1 nM range and competed with transforming growth factor-beta to bind to the cell surface receptor in vitro.     

In vitro selection of high-affinity nucleic acid ligands to parasite target molecules

The logic of using nucleic acids as pharmaceutical reagents is in part based on their capacity to interact with high affinity and specificity with other biological components. Considerable progress has been made over the past 10 years in the development of nucleic acid-based drug molecules using a variety of different technologies. One approach is a combinatorial technology that involves an iterative Darwinian-type in vitro evolution process, which has been termed SELEX for 'systematic evolution of ligands by exponential enrichment'. The procedure is a highly efficient method of identifying rare ligands from combinatorial nucleic acid libraries of very high complexity. It allows the selection of nucleic acid molecules with desired functions and it has been instrumental in the identification of a number of synthetic DNA and RNA molecules, so-called aptamers that recognise ligands of different chemical origin. The method is fast, it does not require special equipment and the selected aptamers typically bind their target with high affinity and high specificity. Here we summarise the recent examples of the SELEX technique within the context of identifying high-affinity ligands against parasite target molecules.     

Assays for cytokines using aptamers

Aptamers are short nucleic acid sequences that are used as ligands to bind their targets with high affinity. They are generated via the combinatorial chemistry procedure systematic evolution of ligands by exponential enrichment (SELEX). Aptamers have shown much promise towards detection of a variety of protein targets, including cytokines. Specifically, for the determination of cytokines and growth factors, several assays making use of aptamers have been developed, including aptamer-based enzyme-linked immunosorbent assays, antibody-linked oligonucleotide assay, fluorescence (anisotropy and resonance energy transfer) assays, and proximity ligation assays. In this article, the concept of aptamer selection using SELEX and the assay formats using aptamers for the detection of cytokines are discussed.